MedTrace Logo

Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy

NCT01261143 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2012-04-25

No results posted yet for this study

Summary

The purpose of this study is to determine the:

Primary end point

* change of Total symptom score

Secondary end point

* neurological test

Conditions

  • Diabetic Neuropathies

Interventions

DRUG

BK-C-0701

tablet, 8 weeks

Sponsors & Collaborators

  • Bukwang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01261143 on ClinicalTrials.gov